Key Oncolytic Virotherapy Market Players:
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Replimune Group Inc.
- Oncolytics Biotech Inc.
- Sorrento Therapeutics Inc.
- PsiOxus Therapeutics Ltd.
- Transgene S.A.
- SillaJen Inc.
- Genelux Corporation
- Viralytics Ltd.
- Shanghai Sunway Biotech Co. Ltd.
- Targovax ASA
- Lokon Pharma AB
- Vyriad Inc.
- Oncorus Inc.
- VCN Biosciences
- CG Oncology Inc.
- Daiichi Sankyo (DELYTACT)
- Pfizer Inc.
- Merck & Co. Inc.
- Transgene Biotek Ltd.
A few biotech players appear to dominate the oncolytic virotherapy space, capturing over half of the market. A second layer of global players in Europe, Asia, and Oceania—also expanding their products in a myriad of viral platforms through partnerships, regulatory success, and through combination therapy clinical trials. Now, there is a growing number of Japanese, Indian, and other local developers. Multi-national pharmaceutical companies such as Pfizer and Merck continue to support development mostly through partnerships and investing in research and development (R&D). The competitive landscape signifies an exodus out of single-viral modalities and an influx of regional oncolytic virotherapy development.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2025, the industry size of oncolytic virotherapy is estimated at USD 20.36 billion.
The global Oncolytic Virotherapy Market size was valued at USD 20.36 billion in 2025 and is projected to reach USD 111.76 billion by the end of 2035, rising at a CAGR of 18.89% during the forecast period, from, 2026-2035. In 2026, the industry size of oncolytic virotherapy is assessed at USD 25.03 billion.
Key players in the market are Amgen Inc., Replimune Group Inc., Oncolytics Biotech Inc., Sorrento Therapeutics Inc., PsiOxus Therapeutics Ltd., Transgene S.A., SillaJen Inc., Genelux Corporation, Viralytics Ltd., Shanghai Sunway Biotech Co. Ltd, and other.
The hospitals segment is estimated to account for the largest share of 67% in the oncolytic virotherapy market over the discussed timeframe.
North America is expected to capture the highest share of 34% in the global oncolytic virotherapy market by the end of 2035.
